Greg Williams is internationally recognised as an experienced litigation lawyer with particular expertise in the conduct of class actions and product liability litigation.

Greg's experience ranges from acting in large-scale class actions for the pharmaceutical and banking industries to advising on regulatory issues, investigations advertising and labelling requirements, and managing product safety issues and recalls.

Greg has particular experience in acting for clients operating in the pharmaceutical and medical devices industries where his science qualifications and laboratory experience give him a special insight into and understanding of his clients' commercial imperatives and legal needs.

Read More

Expertise

Expand all

Class Actions

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Storm:
 Greg led the team representing CBA in class action proceedings brought by former clients and the financial advisory business Storm.  The trial ran for more than 65 sitting days over more than eight months.

Gravigard (Copper 7) intrauterine contraceptive device (IUD):
 Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

See Class Actions

Product Liability

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Gravigard (Copper 7) intrauterine contraceptive device (IUD):
 Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

See Product Liability

Litigation and Dispute Resolution

Class actions and product liability

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Storm:
 Greg led the team representing CBA in class action proceedings brought by former clients and the financial advisory business Storm.  The trial ran for more than 65 sitting days over more than eight months.

Gravigard (Copper 7) intrauterine contraceptive device (IUD):
 Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Dust Diseases Tribunal of NSW:
 Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.

Pharmaceutical and medical devices

Pharmaceutical company:
 Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.


See Litigation and Dispute Resolution

Pharmaceutical and Medical Devices

Pharmaceutical Benefits Scheme: Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.

Pharmaceutical company: Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.


See Pharmaceutical and Medical Devices

Healthcare and Life Sciences

Class actions and product liability

Vioxx: Greg appeared as junior counsel in a three-month Federal Court trial in the Australian Vioxx class action litigation.

Gravigard (Copper 7) intrauterine contraceptive device (IUD):
 Greg acted in the successful defence of G D Searle & Co and Monsanto Corporation in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device (IUD).

Roche Products Pty Ltd:
 Greg represented Roche Products in the successful defence of litigation concerning its prescription acne treatment, Roaccutane.

Dust Diseases Tribunal of NSW:
 Greg has appeared in the Dust Diseases Tribunal of NSW for a number of clients in the construction, shipping and oil refining industries.

Pharmaceutical and medical devices

Pharmaceutical Benefits Scheme:
 Greg advises clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.

Pharmaceutical company:
 Greg is representing a pharmaceutical company in an AAT challenge against the TGA's refusal to register a prescription pharmaceutical on the ARTG.


Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.


See Healthcare and Life Sciences

White Collar Crime and Investigations

Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint.


See White Collar Crime and Investigations

Investigations and Crisis Management

Anti-corruption and global legal obligations

Greg is conducted an audit of medical device company's consultancy and other contract arrangements, for the purposes of managing its risk and exposure under the US Foreign Corrupt Practices Act (FCPA).

Greg assisted a pharmaceutical company in relation to allegations that it provided improper benefits to one of its customers.  The matter involved conducting an investigation, a subsequent review of the company's contractual templates and assisting with a Medicines Australia Code of Conduct complaint. 

See Investigations and Crisis Management

Knowledge

    Related knowledge information is loading